BridgeMD
New treatment option for ARDS (Acute Respiratory Distress Syndrome)
Official title Real-Time Algorithm-Driven Ventilation Feedback to Improve Lung-Protective Ventilation in Patients With ARDS (REALVENT-study)
ClinicalTrials.gov ID: NCT07307066
What this study is testing
- What it's testing
- The REALVENT trial is designed to evaluate whether a real-time, algorithm-driven ventilation feedback strategy can improve lung-protective ventilation (LPV) achievement rates in critically ill patients receiving invasive mechanical ventilation. This multicentre randomised controlled trial will compare real-time respiratory waveform monitoring with automated feedback against standard ICU care.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Age between 18 and 75 years
- Receiving invasive mechanical ventilation via endotracheal intubation at the time of screening
- Initiation of invasive mechanical ventilation within the past 24 hours
- PaO₂/FiO₂ ≤ 200 mmHg on PEEP ≥ 8 cmH₂O or, if arterial blood gas is unavailable: SpO₂/FiO₂ ≤ 235 with SpO₂ ≤ 97%
- Chest imaging (chest X-ray or CT) showing bilateral pulmonary infiltrates not fully explained by pleural effusions, lobar collapse, or pulmonary...
You likely can't join if
- Receipt of extracorporeal membrane oxygenation (ECMO) or high-frequency oscillatory ventilation at screening
- Brain death or anticipated withdrawal of life-sustaining treatment within 72 hours
- Pregnancy
- Known neuromuscular disease affecting spontaneous respiratory effort
- Prisoners or individuals unable to provide informed consent or surrogate consent
- Simultaneous enrollment in another treatment ICU study
See the full eligibility criteria
- Age between 18 and 75 years
- Receiving invasive mechanical ventilation via endotracheal intubation at the time of screening
- Initiation of invasive mechanical ventilation within the past 24 hours
- PaO₂/FiO₂ ≤ 200 mmHg on PEEP ≥ 8 cmH₂O or, if arterial blood gas is unavailable: SpO₂/FiO₂ ≤ 235 with SpO₂ ≤ 97%
- Chest imaging (chest X-ray or CT) showing bilateral pulmonary infiltrates not fully explained by pleural effusions, lobar collapse, or pulmonary nodules
- Respiratory failure not fully explained by cardiac failure or fluid overload
- Expected to require invasive mechanical ventilation for ≥ 72 hours after enrollment
- Receipt of extracorporeal membrane oxygenation (ECMO) or high-frequency oscillatory ventilation at screening
- Brain death or anticipated withdrawal of life-sustaining treatment within 72 hours
- Pregnancy
- Known neuromuscular disease affecting spontaneous respiratory effort
- Prisoners or individuals unable to provide informed consent or surrogate consent
- Simultaneous enrollment in another treatment ICU study
- Lack of digital infrastructure for real-time ventilator waveform acquisition
The study team makes the final eligibility decision.
Where it's taking place
- Qujing, Yunnan, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Qujing, Yunnan, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.